Izetafin

Sodium hydrogen carbonate, potassium chloride, sodium chloride, sodium sulfate anhydrous and macrogol 3, the active ingredients in Izetafin, are presented as an oral solution for oral use. They are employed to correct electrolyte disturbances and to provide an osmotic laxative effect in adult patients.

GNH USA supplies Izetafin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Izetafin is a combined electrolyte and osmotic laxative formulation used in clinical settings for fluid and electrolyte management and bowel preparation.

- Electrolyte imbalance: restores sodium, potassium and chloride levels in patients with dehydration. - Constipation: provides an osmotic laxative effect to facilitate bowel movements. - Diagnostic procedure preparation: used as a bowel cleansing agent before colonoscopy or imaging studies.

Izetafin may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild discomfort in the stomach. - Abdominal bloating: feeling of fullness or swelling. - Diarrhea: loose stools occurring after dosing. - Flatulence: increased intestinal gas. - Electrolyte disturbance: occasional mild shifts in serum levels. - Headache: transient mild pain.

Serious or Rare Side Effects: - Severe dehydration: marked loss of fluids requiring medical attention. - Electrolyte imbalance: significant hypo‑ or hyper‑natremia or hyper‑kalemia. - Allergic reaction: rash, itching, or swelling. - Abdominal pain: persistent or severe discomfort. - Renal impairment: worsening kidney function in susceptible individuals. - Hypotension: low blood pressure due to fluid shifts.

Before using Izetafin, consider the following safety measures.

- Assess hydration status: ensure patient is not severely dehydrated before administration. - Monitor electrolytes: check serum sodium, potassium and chloride levels during therapy. - Renal function: evaluate kidney function in patients with existing renal disease. - Pregnancy and lactation: use only if clearly needed and prescribed by a healthcare professional. - Concomitant laxatives: avoid simultaneous use of other osmotic agents to prevent excessive fluid loss. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Izetafin may interact with other medicines; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid): - Loop diuretics: may exacerbate electrolyte loss and dehydration. - Potassium‑sparing agents: risk of hyper‑kalemia when combined. - Antihypertensives: possible additive blood pressure lowering effect.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and electrolytes. - NSAIDs: may affect renal perfusion when combined with electrolyte shifts. - Other oral laxatives: increase risk of severe diarrhea and electrolyte disturbances.